Patient Guide to Support Services

Coherus BioSciences

Coherus COMPLETE
844-483-3692

Coherus BioSciences’ Coherus COMPLETE offers comprehensive reimbursement and patient support services for patients receiving treatment with Udenyca (pegfilgrastim-cbqv) who are unable to afford the medication, along with provider service programs to help access Udenyca and secure patient reimbursements.

Udenyca, a biosimilar to Neulasta (pegfilgrastim), is a leukocyte growth factor indicated to decrease the incidence of febrile neutropenia in patients with nonmyeloid malignancies who are receiving myelosuppressive anticancer drugs (Table).

Coherus Complete

Coherus COMPLETE provides several financial assistance options for patients who have been prescribed Udenyca.

Co-Pay Assistance Program reduces out-of-pocket costs for eligible, commercially insured patients.

Patient Assistance Program provides Udenyca to eligible uninsured and underinsured patients.

Product Replacement Program provides replacement Udenyca after a documented claims denial, and helps eligible patients find alternative financial support through independent foundations.

Provider support services are facilitated through the Coherus COMPLETE Provider Portal; talking to reimbursement specialists is available to help secure access and reimbursement for patients. Available reimbursement support services include:

  • Assistance with the verification of insurance and benefits details
  • Udenyca-specific coding, billing details, and claims appeal process
  • Prior authorization requirements and facilitation.

Eligibility

Co-Pay Assistance Program

To qualify for the Coherus COMPLETE Co-Pay Assistance Program, patients must have commercial insurance and not be covered under Medicare, Medicaid, or any federally or state-funded insurance.

Patient Assistance Program

To qualify for the Coherus COMPLETE Patient Assistance Program, patients must not be insured or be underinsured with commercial or government-sponsored insurance.

Product Replacement Program

To qualify for the Coherus COMPLETE Product Replacement Program, a qualifying claims denial must be available, in which the provider has followed and documented the approved process.

Application & Enrollment

For information on enrollment in Coherus COMPLETE services, call 844-483-3692 or e-mail This email address is being protected from spambots. You need JavaScript enabled to view it.. Information may also be requested online.

Table Coherus Oncology Drug

Drug
Indications
Patient support programs

Drug
Udenyca (pegfilgrastim-cbqv)
Indication
Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: